Identification

Name
Netilmicin
Accession Number
DB00955  (APRD00232)
Type
Small Molecule
Groups
Approved, Investigational
Description

Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.

Structure
Thumb
Synonyms
  • 1-N-Ethylsisomicin
  • Netilmycin
Product Ingredients
IngredientUNIICASInChI Key
Netilmicin sulfateS741ZJS97U56391-57-2Not applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Netromycin Inj 100mg/mlSolution100 mgIntramuscular; IntravenousSchering Plough1981-12-312004-07-21Canada
Netromycin Inj 50mg/mlSolution50 mgIntramuscular; IntravenousSchering Plough1981-12-312004-07-21Canada
International/Other Brands
Netromycin
Categories
UNII
4O5J85GJJB
CAS number
56391-56-1
Weight
Average: 475.587
Monoisotopic: 475.30059868
Chemical Formula
C21H41N5O7
InChI Key
CIDUJQMULVCIBT-MQDUPKMGSA-N
InChI
InChI=1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11-,12+,13-,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1
IUPAC Name
(2R,3R,4R,5R)-2-{[(1S,2S,3R,4S,6R)-4-amino-3-{[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy}-6-(ethylamino)-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol
SMILES
CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O

Pharmacology

Indication

For the treatment of bacteremia, septicaemia, respiratory tract infections, skin and soft-tissue infection, burns, wounds, and peri-operative infections caused by susceptible strains.

Pharmacodynamics

Netilmicin is a semisynthetic, water soluble antibiotic of the aminoglycoside group, produced by the fermentation of Micromonospora inyoensis, a species of actinomycete. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. It is active at low concentrations against a wide variety of pathogenic bacteria including Escherichia coli, bacteria of the Klebsiella-Enterobacter-Serratia group, Citrobacter sp., Proteus sp. (indole-positive and indole-negative), including Proteus mirabilis, P. morganii, P. rettgrei, P. vulgaris, Pseudomonas aeruginosa and Neisseria gonorrhoea. Netilmicin is also active in vitro against isolates of Hemophilus influenzae, Salmonella sp., Shigella sp. and against penicillinase and non-penicillinase-producing Staphylococcus including methicillin-resistant strains. Some strains of Providencia sp., Acinetobacter sp. and Aeromonas sp. are also sensitive to netilmicin. Many strains of the above organisms which are found to be resistant to other aminoglycosides, such as kanamycin, gentamicin, tobramycin and sisomicin, are susceptible to netilmicin in vitro. Occasionally, strains have been identified which are resistant to amikacin but susceptible to netilmicin. The combination of netilmicin and penicillin G has a synergistic bactericidal effect against most strains of Streptococcus faecalis (enterococcus). The combined effect of netilmicin and carbenicillin or ticarcillin is synergistic for many strains of Pseudomonas aeruginosa. In addition, many isolates of Serratia, which are resistant to multiple antibiotics, are inhibited by synergistic combinations of netilmicin with carbenicillin, azlocillin, mezlocillin, cefamandole, cefotaxime or moxalactam. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

Mechanism of action

Aminoglycosides like netilmicin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically netilmicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes, leaving the bacterium unable to synthesize proteins vital to its growth.

TargetActionsOrganism
A30S ribosomal protein S12
inhibitor
Escherichia coli (strain K12)
A16S rRNA
inhibitor
Enteric bacteria and other eubacteria
Absorption

Rapidly and completely absorbed after IM administration, peak serum levels were achieved within 30-60 minutes. Aminoglycosides are poorly absorbed orally. Topical absorption is also poor unless severe skin damage is present.

Volume of distribution
Not Available
Protein binding

Protein-binding of is low and depends on the test conditions (mainly the concentration of cations in the test medium).

Metabolism

No evidence of metabolic transformation, typically 80% is recoverable in the urine within 24 hours

Route of elimination
Not Available
Half life

2.5 hours

Clearance
Not Available
Toxicity

Netilmicin has nephrotoxic and ototoxic potential. Nephrotoxicity occurs via drug accumulation in renal proximal tubular cells resulting in cellular damage. Tubular cells may regenerate despite continued exposure and nephrotoxicity is usually mild and reversible. Netilmicin is less nephrotoxic than neomycin, gentamicin, tobramycin, and amikacin, likely due to a reduced number of cationic amino groups in its structure. Otoxicity occurs as a result of irreversible damage to hair cells of the cochlea and/or summit of the ampullar cristae in the vestibular complex caused drug accumulation in the endolymph and perilymph of the inner ear. Otoxicity appears to be correlated to total exposure and may be cumulative with further doses of aminoglycosides or other ototoxic drugs (e.g. cisplatin, furosemide). High frequency hearing loss is followed by low frequency hearing loss, which may be followed by retrograde degeneration of the auditory nerve. Vestibular toxicity may cause vertigo, nausea and vomiting, dizziness and loss of balance.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategory
Netilmicin Action PathwayDrug action
Netilmicin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
AceclofenacAceclofenac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Experimental, Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Netilmicin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Netilmicin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumNetilmicin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidNetilmicin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Netilmicin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Netilmicin.Approved, Investigational, Vet Approved
AmoxicillinThe serum concentration of Netilmicin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
AmpicillinThe serum concentration of Netilmicin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
ApocyninApocynin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Netilmicin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumNetilmicin may increase the respiratory depressant activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateNetilmicin may increase the respiratory depressant activities of Atracurium besylate.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Netilmicin.Approved, Vet Approved
AzapropazoneAzapropazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Netilmicin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Netilmicin can be decreased when it is combined with Azlocillin.Approved
AzosemideThe serum concentration of Netilmicin can be increased when it is combined with Azosemide.Investigational
BacampicillinThe serum concentration of Netilmicin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Netilmicin is combined with Bacitracin.Approved, Vet Approved
BalsalazideBalsalazide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Netilmicin.Investigational
BendazacBendazac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Netilmicin.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Netilmicin.Approved, Illicit
BenzydamineBenzydamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Netilmicin.Approved
BenzylpenicillinThe serum concentration of Netilmicin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Netilmicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
Botulinum Toxin Type ANetilmicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BNetilmicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BromfenacBromfenac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Netilmicin.Approved
BucillamineBucillamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Experimental
BumadizoneBumadizone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
BumetanideThe serum concentration of Netilmicin can be increased when it is combined with Bumetanide.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Netilmicin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Netilmicin.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Netilmicin.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental, Investigational
CarbenicillinThe serum concentration of Netilmicin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Netilmicin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinNetilmicin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Netilmicin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
CefaclorCefaclor may increase the nephrotoxic activities of Netilmicin.Approved
CefamandoleCefamandole may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
CefbuperazoneCefbuperazone may increase the nephrotoxic activities of Netilmicin.Experimental
CefcapeneCefcapene may increase the nephrotoxic activities of Netilmicin.Experimental
CefdinirCefdinir may increase the nephrotoxic activities of Netilmicin.Approved
CefditorenCefditoren may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
CefepimeCefepime may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
CefetametCefetamet may increase the nephrotoxic activities of Netilmicin.Experimental
CefiximeCefixime may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
CefmenoximeCefmenoxime may increase the nephrotoxic activities of Netilmicin.Approved
CefmetazoleCefmetazole may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
CefminoxCefminox may increase the nephrotoxic activities of Netilmicin.Approved
CefodizimeCefodizime may increase the nephrotoxic activities of Netilmicin.Experimental
CefonicidCefonicid may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
CefoperazoneCefoperazone may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
CeforanideCeforanide may increase the nephrotoxic activities of Netilmicin.Approved
CefotaximeCefotaxime may increase the nephrotoxic activities of Netilmicin.Approved
CefotetanCefotetan may increase the nephrotoxic activities of Netilmicin.Approved
CefotiamCefotiam may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
CefoxitinCefoxitin may increase the nephrotoxic activities of Netilmicin.Approved
CefozopranCefozopran may increase the nephrotoxic activities of Netilmicin.Experimental
CefpiramideCefpiramide may increase the nephrotoxic activities of Netilmicin.Approved
CefpiromeCefpirome may increase the nephrotoxic activities of Netilmicin.Approved
CefpodoximeCefpodoxime may increase the nephrotoxic activities of Netilmicin.Approved, Vet Approved
CefprozilCefprozil may increase the nephrotoxic activities of Netilmicin.Approved
CefsulodinCefsulodin may increase the nephrotoxic activities of Netilmicin.Experimental
CeftazidimeCeftazidime may increase the nephrotoxic activities of Netilmicin.Approved
CeftibutenCeftibuten may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
CeftizoximeCeftizoxime may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
CeftriaxoneCeftriaxone may increase the nephrotoxic activities of Netilmicin.Approved
CefuroximeCefuroxime may increase the nephrotoxic activities of Netilmicin.Approved
CelecoxibCelecoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Netilmicin.Approved
ChloroquineChloroquine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Netilmicin.Approved
ChlorthalidoneThe serum concentration of Netilmicin can be increased when it is combined with Chlorthalidone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
CisatracuriumNetilmicin may increase the respiratory depressant activities of Cisatracurium.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Netilmicin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Netilmicin.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Netilmicin.Approved, Vet Approved
Clodronic AcidNetilmicin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Netilmicin can be decreased when it is combined with Cloxacillin.Approved, Investigational, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Netilmicin.Approved, Illicit
ColistimethateNetilmicin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
CyclacillinThe serum concentration of Netilmicin can be decreased when it is combined with Cyclacillin.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Netilmicin.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Netilmicin is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Netilmicin.Experimental
DecamethoniumNetilmicin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Netilmicin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Netilmicin is combined with Desvenlafaxine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Netilmicin.Approved
DiclofenacThe risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Netilmicin.Approved, Vet Approved
DicloxacillinThe serum concentration of Netilmicin can be decreased when it is combined with Dicloxacillin.Approved, Investigational, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Netilmicin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Netilmicin.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Netilmicin.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Netilmicin.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Netilmicin.Approved, Investigational
Domoic AcidNetilmicin may increase the respiratory depressant activities of Domoic Acid.Experimental
DotarizineThe risk or severity of adverse effects can be increased when Netilmicin is combined with Dotarizine.Investigational
DoxacuriumNetilmicin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Netilmicin.Approved, Vet Approved
DroxicamDroxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Withdrawn
DuvelisibDuvelisib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Netilmicin.Approved, Investigational
EpicillinThe serum concentration of Netilmicin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Etacrynic acidThe serum concentration of Netilmicin can be increased when it is combined with Etacrynic acid.Approved, Investigational
EtanerceptEtanercept may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
EthanolNetilmicin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthenzamideEthenzamide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Netilmicin.Approved
Etidronic acidNetilmicin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Netilmicin.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational, Nutraceutical
ExisulindExisulind may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Netilmicin.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Withdrawn
FlomoxefFlomoxef may increase the nephrotoxic activities of Netilmicin.Investigational
FlucloxacillinThe serum concentration of Netilmicin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Netilmicin.Approved
FlunixinFlunixin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Netilmicin is combined with Fluoxetine.Approved, Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Netilmicin.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Netilmicin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Netilmicin is combined with Fluvoxamine.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Netilmicin.Approved
FurosemideThe serum concentration of Netilmicin can be increased when it is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Netilmicin.Approved, Investigational
GallamineNetilmicin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideNetilmicin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Netilmicin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Netilmicin.Approved, Investigational
HigenamineHigenamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
HydrocodoneNetilmicin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Netilmicin can be increased when it is combined with Hydroflumethiazide.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Netilmicin.Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Netilmicin.Approved
IbandronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Netilmicin.Approved
IbuproxamIbuproxam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Withdrawn
IpratropiumThe therapeutic efficacy of Ipratropium can be decreased when used in combination with Netilmicin.Approved
IsoxicamIsoxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Vet Approved
KetorolacThe risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Netilmicin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Netilmicin.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Netilmicin.Experimental
LatamoxefLatamoxef may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
LeflunomideLeflunomide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Netilmicin.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Netilmicin.Approved
LisofyllineLisofylline may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
LoracarbefLoracarbef may increase the nephrotoxic activities of Netilmicin.Investigational, Withdrawn
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Netilmicin.Approved, Investigational
LornoxicamLornoxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Netilmicin is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Netilmicin is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Netilmicin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Magnesium sulfateThe therapeutic efficacy of Netilmicin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Netilmicin is combined with Magnesium Trisilicate.Approved
MannitolMannitol may increase the nephrotoxic activities of Netilmicin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
MecamylamineNetilmicin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Netilmicin.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational, Withdrawn
MetampicillinThe serum concentration of Netilmicin can be decreased when it is combined with Metampicillin.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Netilmicin.Approved
MethyclothiazideThe serum concentration of Netilmicin can be increased when it is combined with Methyclothiazide.Approved
MeticillinThe serum concentration of Netilmicin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Netilmicin.Experimental
MetocurineNetilmicin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideNetilmicin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Withdrawn
MezlocillinThe serum concentration of Netilmicin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumNetilmicin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Netilmicin can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftifineNaftifine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NaproxenThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Netilmicin.Approved, Vet Approved
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Netilmicin.Approved, Vet Approved
NeosaxitoxinNetilmicin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Netilmicin is combined with Nicotine.Approved
NifenazoneNifenazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NimesulideThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Netilmicin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Netilmicin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Netilmicin.Approved
OrgoteinOrgotein may decrease the excretion rate of Netilmicin which could result in a higher serum level.Vet Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Netilmicin.Experimental, Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Netilmicin.Approved
OxacillinThe serum concentration of Netilmicin can be decreased when it is combined with Oxacillin.Approved, Investigational
OxaprozinOxaprozin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Netilmicin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Netilmicin.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Withdrawn
PalmidrolPalmidrol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental, Nutraceutical
PamidronateNetilmicin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumNetilmicin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Netilmicin is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Netilmicin is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
PenamecillinThe serum concentration of Netilmicin can be decreased when it is combined with Penamecillin.Experimental
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Netilmicin.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Netilmicin.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Netilmicin.Approved, Investigational
PhenoxymethylpenicillinThe serum concentration of Netilmicin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Netilmicin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
PipecuroniumNetilmicin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Netilmicin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe serum concentration of Netilmicin can be increased when it is combined with Piretanide.Approved
PirfenidonePirfenidone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Netilmicin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Netilmicin can be decreased when it is combined with Pivmecillinam.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Netilmicin is combined with Polymyxin B Sulfate.Approved, Vet Approved
PramipexoleNetilmicin may increase the sedative activities of Pramipexole.Approved, Investigational
PranoprofenPranoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental, Investigational
PregabalinThe therapeutic efficacy of Netilmicin can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
Procaine benzylpenicillinThe serum concentration of Netilmicin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Netilmicin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Netilmicin.Approved, Investigational
PropacetamolPropacetamol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Netilmicin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Netilmicin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Netilmicin is combined with Pseudoephedrine.Approved
PTC299PTC299 may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Netilmicin.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Netilmicin.Approved
QuinethazoneThe serum concentration of Netilmicin can be increased when it is combined with Quinethazone.Approved
RapacuroniumNetilmicin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateNetilmicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Netilmicin is combined with Rizatriptan.Approved
RocuroniumNetilmicin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational, Withdrawn
RopiniroleNetilmicin may increase the sedative activities of Ropinirole.Approved, Investigational
SalicylamideSalicylamide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Salicylic acidThe risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Netilmicin.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Netilmicin.Approved, Investigational
SemapimodSemapimod may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
SuccinylcholineNetilmicin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbenicillinThe serum concentration of Netilmicin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Netilmicin.Approved
SulindacThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Netilmicin.Approved, Investigational
SultamicillinThe serum concentration of Netilmicin can be decreased when it is combined with Sultamicillin.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Netilmicin is combined with Sumatriptan.Approved, Investigational
SuprofenSuprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Netilmicin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
Technetium Tc-99m etidronateNetilmicin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateNetilmicin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Netilmicin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Netilmicin.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Netilmicin.Investigational
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Netilmicin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidNetilmicin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
Tolfenamic AcidThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Netilmicin.Approved, Investigational
TolmetinTolmetin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Netilmicin.Approved
TorasemideThe serum concentration of Netilmicin can be increased when it is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Netilmicin.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Netilmicin which could result in a higher serum level.Experimental
TrichlormethiazideThe serum concentration of Netilmicin can be increased when it is combined with Trichlormethiazide.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Netilmicin.Approved
TriptolideTriptolide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Investigational
Trolamine salicylateThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Netilmicin.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Netilmicin.Approved
TubocurarineNetilmicin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Netilmicin.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Netilmicin.Approved
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Netilmicin.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Netilmicin is combined with Venlafaxine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Netilmicin.Investigational
ZaltoprofenZaltoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Netilmicin.Approved
ZileutonZileuton may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Zoledronic acid.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Netilmicin is combined with Zolmitriptan.Approved, Investigational
ZolpidemNetilmicin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracZomepirac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Netilmicin.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Chou-Hong Tann, Tiruvettipuram K. Thiruvengadam, John S. Chiu, Cesar Colon, "Process for preparing netilmicin." U.S. Patent US4831123, issued June, 1966.

US4831123
General References
  1. Hemsworth S, Nunn AJ, Selwood K, Osborne C, Jones A, Pizer B: Once-daily netilmicin for neutropenic pyrexia in paediatric oncology. Acta Paediatr. 2005 Mar;94(3):268-74. [PubMed:16028643]
  2. Klingenberg C, Smabrekke L, Lier T, Flaegstad T: Validation of a simplified netilmicin dosage regimen in infants. Scand J Infect Dis. 2004;36(6-7):474-9. [PubMed:15307571]
  3. Brooks JR, Marlow N, Reeves BC, Millar MR: Use of once-daily netilmicin to treat infants with suspected sepsis in a neonatal intensive care unit. Biol Neonate. 2004;86(3):170-5. Epub 2004 Jun 29. [PubMed:15237240]
External Links
Human Metabolome Database
HMDB15090
KEGG Drug
D08268
KEGG Compound
C07657
PubChem Compound
441306
PubChem Substance
46507404
ChemSpider
20152952
ChEBI
7528
ChEMBL
CHEMBL1572
Therapeutic Targets Database
DAP000404
PharmGKB
PA164754913
Wikipedia
Netilmicin
ATC Codes
S01AA23 — NetilmicinJ01GB07 — Netilmicin
MSDS
Download (57 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
4CompletedTreatmentPneumonia Ventilator Associated1

Pharmacoeconomics

Manufacturers
  • Schering corp sub schering plough corp
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntramuscular; Intravenous100 mg
SolutionIntramuscular; Intravenous50 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility100 mg/mLNot Available
logP-3Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.2 mg/mLALOGPS
logP-1.4ALOGPS
logP-3.5ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)12.55ChemAxon
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area199.73 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity119.84 m3·mol-1ChemAxon
Polarizability50.76 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9129
Blood Brain Barrier-0.9912
Caco-2 permeable-0.7057
P-glycoprotein substrateSubstrate0.8191
P-glycoprotein inhibitor IInhibitor0.5133
P-glycoprotein inhibitor IINon-inhibitor0.9479
Renal organic cation transporterNon-inhibitor0.8985
CYP450 2C9 substrateNon-substrate0.8475
CYP450 2D6 substrateNon-substrate0.837
CYP450 3A4 substrateSubstrate0.5494
CYP450 1A2 substrateNon-inhibitor0.8995
CYP450 2C9 inhibitorNon-inhibitor0.9098
CYP450 2D6 inhibitorNon-inhibitor0.9237
CYP450 2C19 inhibitorNon-inhibitor0.9033
CYP450 3A4 inhibitorNon-inhibitor0.9691
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8932
Ames testNon AMES toxic0.7193
CarcinogenicityNon-carcinogens0.9266
BiodegradationNot ready biodegradable0.9944
Rat acute toxicity2.0963 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.981
hERG inhibition (predictor II)Non-inhibitor0.6924
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminocyclitol glycosides
Alternative Parents
O-glycosyl compounds / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Monosaccharides / Tertiary alcohols / 1,2-aminoalcohols / Oxacyclic compounds / Dialkylamines
show 4 more
Substituents
Amino cyclitol glycoside / Glycosyl compound / O-glycosyl compound / Aminocyclitol or derivatives / Cyclohexanol / Cyclohexylamine / Cyclitol or derivatives / Monosaccharide / Oxane / Cyclic alcohol
show 17 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
Gene Name
rpsL
Uniprot ID
P0A7S3
Uniprot Name
30S ribosomal protein S12
Molecular Weight
13736.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
2. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Tuuminen T, Heinasmaki T, Kerttula T: First report of bacteremia by Asaia bogorensis, in a patient with a history of intravenous-drug abuse. J Clin Microbiol. 2006 Aug;44(8):3048-50. [PubMed:16891542]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:49